Literature DB >> 22293538

The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal.

Paiboon Jungsuwadee1, Tianyong Zhao, Elzbieta I Stolarczyk, Christian M Paumi, D Allan Butterfield, Daret K St Clair, Mary Vore.   

Abstract

OBJECTIVE: Doxorubicin-induced acute cardiotoxicity is associated with the Gly671Val (G671V; rs45511401) variant of multidrug resistance-associated protein 1 (MRP1). Doxorubicin redox cycling causes lipid peroxidation and generation of the reactive electrophile, 4-hydroxy-2-trans-nonenal (HNE). Glutathione forms conjugates with HNE, yielding an MRP1 substrate, GS-HNE, whose intracellular accumulation can cause toxicity.
METHODS: We established stable HEK293 cell lines overexpressing wild-type MRP1 (HEKMRP1), G671V (HEKG671V), and R433S (HEKR433S), a variant not associated with doxorubicin-induced cardiotoxicity and investigated the sensitivity of HEKG671V cells to doxorubicin and transport capacity of G671V toward GS-HNE.
RESULTS: In ATP-dependent transport studies using plasma membrane-derived vesicles, the Vmax (pmol/min/mg) for GS-HNE transport was the lowest for G671V (69±4) and the highest for R433S (972±213) compared with wild-type MRP1 (416±22), whereas the Km values were 2.8±0.4, 6.0 or more, and 1.7±0.2 µmol/l, respectively. In cells, the doxorubicin IC50 (48 h) was not different in HEKMRP1 (463 nmol/l) versus HEKR433S (645 nmol/l), but this parameter was significantly lower in HEKG671V (181 nmol/l). HEKG671V retained significantly (approximately 20%) more, whereas HEKR433S retained significantly less intracellular doxorubicin than HEKMRP1. Similarly, HEKG671V cells treated with 1.5 µmol/l of doxorubicin for 24 h retained significantly more GS-HNE. In cells treated with 0.5 µmol/l of doxorubicin for 48 , glutathione and glutathione disulfide levels and the glutathione/glutathione disulfide ratio were significantly decreased in HEKG671V versus HEKMRP1; these values were similar in HEKR433S versus HEKMRP1.
CONCLUSION: These data suggest that decreased MRP1-dependent GS-HNE efflux contributes to increased doxorubicin toxicity in HEKG671V and potentially in individuals carrying the G671V variant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293538      PMCID: PMC3308135          DOI: 10.1097/FPC.0b013e328350e270

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  33 in total

Review 1.  The cardiotoxicity of chemotherapeutic drugs.

Authors:  A Allen
Journal:  Semin Oncol       Date:  1992-10       Impact factor: 4.929

2.  Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation.

Authors:  I Hubatsch; M Ridderström; B Mannervik
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

3.  Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

Authors:  I C Henderson; J C Allegra; T Woodcock; S Wolff; S Bryan; K Cartwright; G Dukart; D Henry
Journal:  J Clin Oncol       Date:  1989-05       Impact factor: 44.544

4.  Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the heart.

Authors:  T Ishikawa; H Esterbauer; H Sies
Journal:  J Biol Chem       Date:  1986-02-05       Impact factor: 5.157

5.  Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1.

Authors:  S K Diah; P K Smitherman; A J Townsend; C S Morrow
Journal:  Toxicol Appl Pharmacol       Date:  1999-06-01       Impact factor: 4.219

6.  Localization of a substrate specificity domain in the multidrug resistance protein.

Authors:  B D Stride; S P Cole; R G Deeley
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

7.  Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat.

Authors:  X Luo; Y Evrovsky; D Cole; J Trines; L N Benson; D C Lehotay
Journal:  Biochim Biophys Acta       Date:  1997-02-27

Review 8.  Anthracycline-induced cardiotoxicity.

Authors:  K Shan; A M Lincoff; J B Young
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

9.  Tissue distribution of the multidrug resistance protein.

Authors:  M J Flens; G J Zaman; P van der Valk; M A Izquierdo; A B Schroeijers; G L Scheffer; P van der Groep; M de Haas; C J Meijer; R J Scheper
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  The hepatocellular metabolism of 4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase, and glutathione S-transferase.

Authors:  D P Hartley; J A Ruth; D R Petersen
Journal:  Arch Biochem Biophys       Date:  1995-01-10       Impact factor: 4.013

View more
  7 in total

Review 1.  Systems biology approaches to adverse drug effects: the example of cardio-oncology.

Authors:  Sherry-Ann Brown; Nicole Sandhu; Joerg Herrmann
Journal:  Nat Rev Clin Oncol       Date:  2015-10-13       Impact factor: 66.675

2.  FUsed in sarcoma is a novel regulator of manganese superoxide dismutase gene transcription.

Authors:  Sanjit Kumar Dhar; Jiayu Zhang; Jozsef Gal; Yong Xu; Lu Miao; Bert C Lynn; Haining Zhu; Edward J Kasarskis; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2013-09-20       Impact factor: 8.401

3.  Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice.

Authors:  Jun Deng; Donna Coy; Wei Zhang; Manjula Sunkara; Andrew J Morris; Chi Wang; Luksana Chaiswing; Daret St Clair; Mary Vore; Paiboon Jungsuwadee
Journal:  J Pharmacol Exp Ther       Date:  2015-09-09       Impact factor: 4.030

4.  Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.

Authors:  Wei Zhang; Jun Deng; Manjula Sunkara; Andrew J Morris; Chi Wang; Daret St Clair; Mary Vore
Journal:  J Pharmacol Exp Ther       Date:  2015-09-09       Impact factor: 4.030

5.  Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.

Authors:  Carolina Dagli-Hernandez; Jéssica Bassani Borges; Elisangela da Silva Rodrigues Marçal; Renata Caroline Costa de Freitas; Augusto Akira Mori; Rodrigo Marques Gonçalves; Andre Arpad Faludi; Victor Fernandes de Oliveira; Glaucio Monteiro Ferreira; Gisele Medeiros Bastos; Yitian Zhou; Volker M Lauschke; Alvaro Cerda; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmaceutics       Date:  2022-04-27       Impact factor: 6.525

6.  Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity.

Authors:  Timothy A McCaffrey; Constantine Tziros; Jannet Lewis; Richard Katz; Robert Siegel; William Weglicki; Jay Kramer; I Tong Mak; Ian Toma; Liang Chen; Elizabeth Benas; Alexander Lowitt; Shruti Rao; Linda Witkin; Yi Lian; Yinglei Lai; Zhaoqing Yang; Sidney W Fu
Journal:  Int J Biol Sci       Date:  2013-04-22       Impact factor: 6.580

7.  Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment ("chemobrain").

Authors:  Jeriel T R Keeney; Xiaojia Ren; Govind Warrier; Teresa Noel; David K Powell; Jennifer M Brelsfoard; Rukhsana Sultana; Kathryn E Saatman; Daret K St Clair; D Allan Butterfield
Journal:  Oncotarget       Date:  2018-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.